8-K: Tenon Medical Reports Strong Q4, Full Year 2025 Growth

Tenon Medical announced record fourth quarter and full year 2025 financial results, driven by increased revenue and gross profit, alongside key product and intellectual property advancements.

Summary

• Fourth quarter 2025 revenue reached $1.5 million, marking a 92% increase compared to the fourth quarter of 2024.
• Full year 2025 revenue was a record $3.9 million, a 20% increase compared to $3.3 million in 2024.
• Gross profit for the fourth quarter of 2025 was $1.0 million, an increase of 188% compared to $0.4 million in the prior year, with a gross margin of 69%.
• Full year 2025 gross profit was a record $2.4 million, a 38% increase compared to $1.7 million in 2024, with a gross margin of 60%.
• Net loss for the fourth quarter of 2025 improved to $2.8 million, or $0.29 per share, from $3.1 million, or $0.98 per share, in the fourth quarter of 2024.
• Net loss for the full year 2025 improved to $12.6 million, or $1.70 per share, from $13.7 million, or $11.26 per share, in 2024.
• Secured FDA 510(k) clearance for its next-generation SImmetry+ SI Joint Fusion System, expanding its portfolio to include a complementary lateral approach.
• Completed initial SImmetry+ procedures at Centers of Excellence, advancing commercial rollout and supporting early surgeon adoption.
• Completed a $2.85 million At-The-Market PIPE financing in Q4 2025 to strengthen its balance sheet and support strategic growth initiatives.
• Closed a private placement of senior convertible notes offering for gross proceeds of $4.3 million in March 2026.
• Expanded intellectual property portfolio with multiple Notices of Allowance from the U.S. Patent and Trademark Office, bringing the global estate to 29 issued U.S. patents, nine international patents, and 31 pending applications.
• Hosted 24 physicians in targeted training sessions for both Catamaran and SImmetry within the fourth quarter of 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by significant revenue and gross profit growth, successful product launches, and strategic capital raises, indicating positive operational momentum and market expansion.

Positives

• Record fourth quarter 2025 revenue of $1.5 million, representing a 92% increase compared to the prior year.
• Record full year 2025 revenue of $3.9 million, a 20% increase compared to 2024, driven by strong second-half momentum.
• Record full year 2025 gross profit of $2.4 million, a 38% increase compared to 2024.
• Significant gross margin improvement: 69% in Q4 2025 (up 23 percentage points) and 60% for the full year 2025 (up 8 percentage points).
• Reduced net loss for both Q4 2025 ($2.8 million vs. $3.1 million) and Full Year 2025 ($12.6 million vs. $13.7 million), indicating improved operating leverage.
• Secured FDA 510(k) clearance for the next-generation SImmetry+ SI Joint Fusion System, broadening the addressable market and supporting diverse surgeon preferences.
• Successfully completed initial SImmetry+ procedures at Centers of Excellence, reinforcing surgeon confidence and supporting broader market expansion.
• Strengthened the balance sheet with a $2.85 million At-The-Market PIPE financing in Q4 2025 and a $4.3 million senior convertible notes offering in March 2026.
• Expanded intellectual property portfolio with multiple Notices of Allowance, enhancing protection around Catamaran and SImmetry technologies.
• Increased number of surgical procedures in the second half of 2025 across both Catamaran and SImmetry+ platforms, primarily due to new physician users.
• Full year 2025 operating expenses decreased to $15.2 million from $15.5 million in 2024, primarily due to reduced general and administrative expenses.

Negatives

• Cash and cash equivalents decreased to $3.8 million as of December 31, 2025, from $6.5 million at December 31, 2024.
• Operating expenses increased in the fourth quarter of 2025 to $3.9 million from $3.5 million in the fourth quarter of 2024, primarily due to higher variable sales and marketing expenses.
• The company continues to report a net loss for both the quarter and the full year, despite improvements.

Risks

• Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors.
• Details on uncertainties that may cause actual results to be materially different are available in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and updated in Form 10-Q filings and other public filings with the SEC.

Future Outlook

Tenon Medical expects to build on current momentum in 2026 with accelerating adoption, improving field productivity, and a tightening cost structure that enhances operating leverage. The company believes its differentiated portfolio, growing surgeon engagement, and strengthened competitive position will drive sustainable growth and deliver increasing value to patients, providers, and shareholders. Net proceeds from the recent financing are expected to fund continued commercial expansion, upcoming product launches, clinical studies, working capital, and general corporate purposes.

Management Comments

• "Our fourth quarter marked a significant period for Tenon, highlighted by FDA clearance of SImmetry+, successful early clinical experience, record procedure growth, and continued commercial expansion." Steve Foster, President and Chief Executive Officer of Tenon Medical.
• "We not only broadened our SI joint fusion platform to support multiple surgical approaches, but we also strengthened our balance sheet and, subsequent to quarter end, expanded our intellectual property estate, further reinforcing the long-term defensibility of our technology." Steve Foster.
• "As we enter 2026, we are building on this momentum with accelerating adoption, improving field productivity, and a tightening cost structure that enhances operating leverage." Steve Foster.
• "With a differentiated portfolio, growing surgeon engagement, and a strengthened competitive position, we believe Tenon is well positioned to drive sustainable growth and deliver increasing value to patients, providers, and shareholders." Steve Foster.

Industry Context

StockSavvy.ai notes that the medical device sector, particularly in specialized areas like SI joint fusion, benefits significantly from product innovation and intellectual property protection. Tenon Medical's FDA clearance for SImmetry+ and expansion of its patent portfolio are critical for maintaining a competitive edge and expanding market share in a growing field focused on less invasive surgical solutions for chronic pain. The focus on multiple surgical approaches (lateral and inferior-posterior) aligns with broader industry trends towards personalized medicine and surgeon preference.

Comparison to Industry Standards

• Tenon Medical's 92% Q4 2025 revenue growth and 20% full-year growth are strong indicators, potentially outperforming some established players in the orthopedic and spinal device market, which often see single to low double-digit growth. For example, larger diversified medical device companies like Medtronic or Stryker typically report more moderate growth in their established segments.
• The gross margin improvement to 69% in Q4 and 60% for the full year is competitive within the medical device industry, where high margins are common due to specialized technology and intellectual property. This compares favorably to companies like NuVasive (acquired by Globus Medical), which historically reported gross margins in the mid-70s, or smaller, innovative players who might start lower but scale up.
• The successful initial procedures at Centers of Excellence for SImmetry+ are crucial for market adoption, mirroring strategies used by companies launching new surgical technologies, such as those in robotic-assisted surgery (e.g., Intuitive Surgical's da Vinci system) or advanced spinal implants.
• The expansion of the IP portfolio to 29 U.S. patents and 9 international patents demonstrates a robust defensive strategy, comparable to the patent portfolios of leading orthopedic companies protecting their core technologies.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance, product innovation, and strategic growth initiatives. Recent capital raises could lead to dilution but also fund growth.
• Patients: Access to new and improved SI joint fusion systems (SImmetry+), offering diverse surgical approaches for debilitating SI joint pain.
• Providers (Surgeons/Hospitals): Expanded portfolio of SI joint fusion systems (Catamaran and SImmetry+) with multiple surgical approaches, supported by training and clinical evidence.
• Employees: Continued commercial expansion and growth initiatives may lead to increased opportunities, particularly in sales and marketing.

Next Steps

• Continued commercial expansion of Catamaran and SImmetry+ platforms.
• Broader market expansion for SImmetry+ in the quarters ahead.
• Advance product launches.
• Expand commercial operations.
• Fund clinical development efforts and clinical studies.
• Development and launch of acquired SiVantage assets.
• Expanding the commercial team.

Key Dates

Recommendation

The company demonstrated significant revenue growth (92% in Q4, 20% for full year), substantial gross profit improvement, and a reduction in net loss, indicating strong operational leverage and increasing market adoption. Key strategic milestones, including FDA clearance for SImmetry+, successful initial procedures, and expansion of intellectual property, position the company for continued growth. Recent capital raises strengthen the balance sheet to fund future expansion. These factors collectively suggest a strong positive trajectory for the company.

Keywords

Tenon Medical, TNON, SI Joint Fusion, SImmetry+, Catamaran, Medical Device, Financial Results, FDA Clearance, Intellectual Property, Sacro-pelvic disorders, Orthopedics